AstraZeneca Pharma India on Monday said it has received approval from the Drugs Controller General of India to import heart failure treatment drug Dapagliflozin tablets. The company has received permission from the DCGI to import pharmaceutical formulations of a new drug for sale, the drug firm said in a regulatory filing.